# A Single‐Center, Open‐Label Study to Evaluate the Efficacy and Tolerability of Retinal Encapsulated in a Novel Biomimetic Exosome in the Treatment of Mild‐To‐Moderate Facial Photodamage

## TL;DR

A new retinal skincare product using a biomimetic exosome improved facial photodamage with minimal irritation in a 12-week study.

## Contribution

A novel retinal formulation using a biomimetic vegan exosome delivery system was developed and tested for photodamaged skin.

## Key findings

- Significant improvements in erythema, skin tone, texture, and lines/wrinkles were observed at all follow-up visits.
- All participants showed improved facial aesthetics by weeks 8 and 12, with 95% expressing satisfaction and willingness to recommend the product.
- No product-related adverse events were reported, indicating good tolerability.

## Abstract

Numerous retinoid‐based skincare products are available over‐the‐counter for photodamaged and photoaged skin, but are associated with objective (e.g., erythema, dryness, flaking, edema) and subjective (e.g., itching, tingling, stinging, burning) tolerability issues. A novel retinal formulation was developed using an engineered biomimetic vegan exosome as a delivery system. The formulation also contains proprietary and potent hyaluronic acid, as well as plant‐based actives commonly used in traditional herbal medicines for their anti‐inflammatory and antioxidant properties.

Evaluate the efficacy and tolerability of this biomimetic exosome‐encapsulated retinal product for treatment of mild‐to‐moderate facial photodamage.

Twenty females aged 35 to 65 years, with Fitzpatrick skin types I‐VI, mild‐to‐moderate facial fine lines and wrinkles, and mild‐to‐moderate facial photodamage, were assessed at screening/baseline and weeks 2, 4, 8, and 12. Investigator‐ and participant‐assessed evaluations were performed at each visit. The primary objective was to demonstrate a decrease in the appearance of fine lines and wrinkles, erythema, as well as a reduction of overall facial photodamage after a 12‐week topical regimen. The secondary objective was to measure the frequency of adverse events throughout the study.

Statistically significant improvements in erythema, skin tone, skin texture, and lines/wrinkles were observed at all follow‐up visits, compared to baseline. At weeks 8 and 12, all participants (100%) displayed improvements in facial aesthetics. Most participants (19/20; 95.00%) were satisfied with the product and would recommend it to others. No product‐related adverse events were reported.

Daily use of this “hydrating retinal” improved signs of facial photodamage with none to mild signs of skin irritation.